A new study published by the National Institute of Health has found that cannabidiol – a cannabis compound – attacks tumor cells, inhibiting them from further growth, by affecting “multiple tumoral features and molecular pathways”.
“In the present study, we found that CBD inhibited U87-MG and T98G cell proliferation and invasiveness in vitro and caused a decrease in the expression of a set of proteins specifically involved in growth, invasion and angiogenesis”, claims the study’s researchers.
“In addition, CBD treatment caused a dose-related down-regulation of ERK and Akt prosurvival signaling pathways in U87-MG and T98G cells and decreased hypoxia inducible factor HIF-1α expression in U87-MG cells.”
They continue; “Taken together, these results provide new insights into the antitumor action of CBD, showing that this cannabinoid affects multiple tumoral features and molecular pathways.”
The study concludes; “As CBD is a non-psychoactive phytocannabinoid that appears to be devoid of side effects, our results support its exploitation as an effective anti-cancer drug in the management of gliomas.”
The study – which can be found by clicking here – was conducted at the Centre of Neuroscience at the University of Insubria in Italy.